Skip to content

Author

Julia R. Herrera

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms between KRASG12D and KRASG12R, mutants with fundame...

Daniel Dorbin, Julia R. Herrera, R. Davidson et al. · 0 citations
Sep 2026

Abstract B060: From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer

Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...

T. McFall, Daniel Dorbin, Julia R. Herrera et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.